NLS Pharmaceutics AG
NASDAQ:NLSP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NLS Pharmaceutics AG
Additional Paid In Capital
NLS Pharmaceutics AG
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Additional Paid In Capital
$72.8m
|
CAGR 3-Years
20%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Novartis AG
SIX:NOVN
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Roche Holding AG
SIX:ROG
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
Oculis Holding AG
NASDAQ:OCS
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
NLS Pharmaceutics AG
Glance View
NLS Pharmaceutics Ltd. engages in the discovery and development of drug therapies to treat rare and complex central nervous systems disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder. The company is headquartered in Stans, Nidwalden and currently employs 6 full-time employees. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.
See Also
What is NLS Pharmaceutics AG's Additional Paid In Capital?
Additional Paid In Capital
72.8m
USD
Based on the financial report for Dec 31, 2024, NLS Pharmaceutics AG's Additional Paid In Capital amounts to 72.8m USD.
What is NLS Pharmaceutics AG's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
29%
Over the last year, the Additional Paid In Capital growth was 19%. The average annual Additional Paid In Capital growth rates for NLS Pharmaceutics AG have been 20% over the past three years , 29% over the past five years .
